NCT03698851

Brief Summary

In recent years, dental implants have gained popularity as the treatment choice for replacement of missing teeth. With this, one of the late biological complications that arise is peri-implantitis. Based on a consensus conference in 2008, peri-implantitis was found in 28% and ≥ 56% of subjects and in 12% and 43% of implant sites (Zitzmann \& Berglundh 2008). Detection of peri-implantitis is currently based on clinical parameters like probing depths and radiographic findings of bone loss. There is however no study that assess the variability of clinical probing and radiographic reading in relation to the true outline of the peri-implantitis lesion. The present study will measure variability of clinical probing and radiographs in relation to the true outline of the peri-implantitis lesion, as well as assess the use of 2 different bone substitutes in regenerating the lesions with a barrier membrane.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 2, 2018

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

August 21, 2018

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 9, 2018

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 22, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 22, 2024

Completed
Last Updated

January 3, 2025

Status Verified

January 1, 2025

Enrollment Period

6.7 years

First QC Date

August 21, 2018

Last Update Submit

January 1, 2025

Conditions

Keywords

Peri-Implantitis lesionDental Implants

Outcome Measures

Primary Outcomes (3)

  • The accuracy of clinical probing pocket depths to the true outline in peri-implantitis lesions

    To determine the accuracy of clinical probing pocket depths (in mm) to the true outline in peri-implantitis lesions

    6 months after GBR

  • The accuracy of peri-apical radiographic readings to the true outline in peri-implantitis lesions

    To determine the accuracy of peri-apical radiographic readings (in mm) to the true outline in peri-implantitis lesions

    6 months after GBR

  • Absolute change from baseline of probing pocket depth (PPD in mm) and the degree of bone fill at re-entry (6 months)

    \- To determine: 1. Absolute change from baseline of probing pocket depth (PPD in mm) 6 months following GBR therapy in test and control 2. The degree of bone fill at re-entry (6 months), as well as radiographically (in mm) following GBR

    6 months after GBR

Study Arms (2)

Test Group

EXPERIMENTAL

Guidor® and Guidor easy-graft® CRYSTAL Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CRYSTAL (Test).

Device: Guidor® and Guidor easy-graft® CRYSTAL

Control Group (C)

ACTIVE COMPARATOR

Guidor® and Guidor easy-graft® CLASSIC Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CLASSIC (Test).

Device: Guidor® and Guidor easy-graft® CLASSIC

Interventions

A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.

Test Group

Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.

Control Group (C)

Eligibility Criteria

Age21 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Medically healthy adults (ASA classification I-II), at least 21 years of age.
  • Diagnosed with peri-implantitis (at least one site with PPD of ≥ 6 mm, a positive bleeding on probing (BOP) and radiographic bone loss of ≥ 2 mm).
  • Had non-surgical therapy performed previously
  • Ability to comply with 6-month study follow-up.

You may not qualify if:

  • Medically compromised subjects (ASA classification III-V).
  • Had not gone through non-surgical therapy
  • Known allergy or other severe adverse reactions to the synthetic membrane and bone substitutes.
  • Self declared pregnancy or intend to conceive.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Dental Centre Singapore

Singapore, 730770, Singapore

Location

MeSH Terms

Conditions

Peri-Implantitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

  • WAH CHING TAN

    National Dental Centre, Singapore

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr, Visiting Specialist (Peridontics), Department of Restorative Dentistry

Study Record Dates

First Submitted

August 21, 2018

First Posted

October 9, 2018

Study Start

March 2, 2018

Primary Completion

November 22, 2024

Study Completion

November 22, 2024

Last Updated

January 3, 2025

Record last verified: 2025-01

Locations